Stomatocytes are typically fabricated from polymersomes through an osmotic-pressure-driven shape transformation process^[22]. Spherical polymersomes are formed by the addition of water to a solution of amphiphilic block copolymers in an organic solvent. Subsequently, the organic solvent is removed from inside the polymersome’s lumen and exchanged by water through dialysis. This leads to osmotic stress and a difference in influx and efflux of solvent. The decreased luminal volume triggers a shape change. In the case of stomatocytes, this shape change follows an oblate pathway, going from discs to the bowl-shaped morphology until the polymer membrane has lost its fluidity due to the removal of the organic solvent and the structure is kinetically trapped. The oblate route is achieved when the membrane displays a negative spontaneous curvature to induce inward folding^[23]. There are some key physicochemical factors that determine the formation of stomatocytes. The composition of block copolymers strongly influences stomatocyte formation. Changing hydrophobic block chemistry alters membrane rigidity and curvature preferences. The membrane must be flexible enough to deform but stable enough to maintain the concave shape. Furthermore, composition of the dialysis solution not only determines actual stomatocyte formation but also the size of the neck region^[24]. Consequently, the combination of the correct polymer composition, membrane curvature and osmotic pressure enables the transformation of a spherical vesicle into a stable bowl-shaped structure.

Amphiphilic block copolymers serve as the fundamental building blocks for the formation of stomatocytes. Through self-assembly, these polymers form well-defined membranes that provide the structural basis for the characteristic bowl-shaped morphology and tunable opening of stomatocytes. The first stomatocytes were reported in 2010 using poly(ethylene glycol)-block-polystyrene (PEG-b-PS)^[21]. In this approach, PEG-b-PS was initially self-assembled in a solvent mixture containing 50% vol % organic solvent (THF : dioxane = 1:1, v/v) and 50% vol % Milli-Q water, followed by dialysis against pure water at room temperature. The organic solvent mixture acts as a plasticizing medium, increasing the conformational mobility of the PS chains and maintaining sufficient membrane permeability to facilitate the shape-transformation process^[25]. Subsequently, biodegradable block copolymers, such as poly(ethylene glycol)-block-poly(D,L-lactide) (PEG-PDLLA), were investigated for the preparation of stomatocytes with improved potential for biomedical applications. In a typical preparation, PEG-PDLLA was dissolved in an organic solvent mixture (THF : dioxane = 1:4, v/v), followed by the addition of an equal volume of water. The resulting vesicles were subsequently subjected to dialysis against a 50 mM NaCl solution at 5 ℃ to induce shape transformation. During dialysis, the change in solvent composition across the vesicular membrane generates an osmotic pressure that promotes solvent diffusion from the vesicle lumen to the external medium. The resulting decrease in the internal volume relative to the membrane area induces membrane buckling and inward deformation, ultimately leading to the formation of the characteristic stomatocyte morphology. The resulting bowl-shaped structures have been characterized by scanning electron microscopy (SEM) and cryogenic transmission electron microscopy (cryo-TEM), as shown in Figure 3.

Importantly, the morphology and physicochemical properties of stomatocytes are strongly influenced by the molecular characteristics of the constituent block copolymers. Key parameters include the hydrophilic-to-hydrophobic block ratio, polymer molecular weight, solvent mixture ratio, and dialysis conditions. Accordingly, careful control over polymer composition and assembly conditions enables the formation of stomatocytes with tunable cavity dimensions, membrane characteristics, and opening sizes.

Unlike conventional spherical polymersomes, stomatocytes exhibit asymmetric morphology that endows them with distinct structural and functional advantages^[30]. Their compartmentalized structure enables the encapsulation of a wide range of therapeutic, diagnostic, and functional cargos. In addition, both the internal cavity and the membrane opening can be engineered to regulate cargo loading, retention, and release, thereby providing control over cargo transport and delivery. Compared with conventional vesicular systems, this asymmetric architecture offers additional opportunities for structural and functional diversification. The key differences between polymersomes and stomatocytes are summarized in Table 1. In particular, the unique open cavity configuration not only facilitates cargo encapsulation and controlled release, but also provides a confined microenvironment that can be further exploited for the development of nanomotors and nanoreactors, expanding the potential applications of stomatocytes in biomedicine and nanotechnology. Importantly, the tunable opening size provides an additional means of regulating molecular exchange and limiting the premature leakage of encapsulated cargos. Cargo retention can be further enhanced through strategies such as enzyme clustering or in situ growth of functional components within the cavity, which physically confines active cargos and reduces their diffusion-driven loss. These approaches are particularly attractive for maintaining a high local concentration of therapeutic or catalytic payloads and for sustaining their activity within the confined cavity. By integrating the compartmentalization and tunable permeability characteristic of vesicular carriers with additional structural and functional capabilities, stomatocytes may offer potential advantages over some conventional nanocarrier systems, thereby offering significant potential for applications in nanomedicine.

Owing to their asymmetric morphology and internal cavities, stomatocytes offer several unique functional advantages for nanomedicine applications. These advantages include high-capacity and multifunctional cargo loading, enhanced protection of sensitive payloads, controlled and stimuli-responsive release, compartmentalization of multiple therapeutics, improved biological interactions, active transport and enhanced tissues penetration, tunable surface engineering, and the ability to serve as platforms for artificial organelles.

Stomatocytes have been effectively applied in cancer therapy [Figure 6]. Their unique structure enables the simultaneous encapsulation of both hydrophilic and hydrophobic therapeutic agents, while their chemically addressable surface allows precise conjugation of targeting ligands, polymers, or stimulus-responsive moieties. These features collectively enhance tumor selectivity, cellular uptake, and spatiotemporal control over therapeutic delivery. One of the earliest and most extensively investigated applications of stomatocytes in nanomedicine is their use as nanocarriers for chemotherapeutic drug delivery^[74,75]. For example, mannose-functionalized stomatocyte nanomotors have demonstrated improved dynamic targeting and cellular uptake in cancer cells^[76]. Beyond conventional chemotherapy, stomatocytes can be used as versatile carriers for a broad range of cancer treatments, including photothermal therapy (PTT), photodynamic therapy (PDT), gene therapy, and immunotherapy. By encapsulating photothermal agents or photosensitizers, stomatocytes enable externally triggered tumor ablation upon near-infrared laser irradiation, offering precise spatial and temporal control over therapeutic activation^[74]. A representative example is the recent study reporting the design and preparation of targeted peptide nanofiber-loaded stomatocytes for combined PDT and PTT treatment, demonstrating the strong potential of stomatocyte-based nanoplatforms for synergistic therapy^[77]. Similarly, nucleic acid therapeutics such as siRNA, miRNA, or mRNA are protected from enzymatic degradation and delivered into tumor cells, enabling gene regulation-based cancer interventions.

In the context of immunotherapy, stomatocytes function as delivery vehicles for immunomodulatory agents, thereby enhancing tumor immune recognition and promoting antitumor immune response^[78,79]. Furthermore, the inherently multicompartmental feature of stomatocytes enables the co-encapsulation of multiple therapeutic payloads within a single nanocarrier system. This includes small-molecule chemotherapeutics (e.g., paclitaxel, cisplatin, irinotecan), nucleic acid therapeutics (e.g., mRNA, siRNA, miRNA), and protein-based therapeutics or enzymes (e.g., L-asparaginase, caspase, and L-arginase). Such versatility allows the rational design of synergistic combination therapies, including chemo-gene therapy, chemo-immunotherapy, and chemo-catalytic therapy, which are particularly promising for overcoming tumor heterogeneity, multidrug resistance, and limited treatment efficacy associated with monotherapies.

Beyond cancer treatment, stomatocytes have recently shown promising potential for antibacterial and anti-biofilm applications. A broad spectrum of antimicrobial payloads, including conventional antibiotics (e.g., vancomycin, ciprofloxacin, and rifampicin), antimicrobial peptides, metal-based antibacterial agents (e.g., silver, copper, and ZnO nanoparticles), bacteriolytic enzymes (e.g., lysozyme), as well as catalytic nanozymes capable of generating reactive oxygen species (ROS) were effectively encapsulated in stomatocytes^[80-82]. Compared with free antimicrobial agents, stomatocyte-mediated delivery offers several significant advantages, including prolonged blood circulation, improved pharmacokinetic profiles, enhanced stability against premature degradation or enzymatic inactivation, reduced systemic toxicity, and increased accumulation at infected tissues through passive or active targeting mechanisms. Furthermore, surface functionalization with bacterial-targeting ligands, antibodies, antimicrobial peptides, or cell membrane coating enables selective recognition of pathogenic microorganisms while minimizing off-target effects on microbiota and healthy tissues^[83,84]. One of the most attractive features of stomatocyte lies in their potential to penetrate bacterial biofilms, which remain one of the major causes of chronic infections. Biofilms consist of densely packed bacterial communities embedded within an extracellular polymeric substance (EPS) matrix that severely limits antibiotic penetration and protects bacteria from host immune responses^[85]. The unique morphology and tunable physicochemical properties of stomatocytes facilitate enhanced penetration into biofilm matrices, thereby improving local drug delivery. Moreover, multifunctional stomatocytes can be engineered to disrupt biofilms through multiple strategies, including enzymatic degradation of EPS components, catalytic ROS generation, photothermal or photodynamic therapy, and localized release of antimicrobial agents.

Recent advances in stomatocyte engineering have enabled the development of next generation antibacterial systems by integrating stimuli-responsive and self-propelled functionalities. For example, pH-responsive stomatocytes selectively release antibacterial agents within the acidic microenvironment of infected tissues, while enzyme-responsive systems exploit bacterial enzymes, such as lipases or proteases, to trigger site-specific drug release. Catalytic stomatocyte nanoreactors capable of producing ROS or other bactericidal species provide an antibiotic-independent strategy for bacterial elimination. Furthermore, autonomously propelled stomatocyte-based nanomotors could potentially facilitate transport through viscous biological fluids and dense biofilm matrices, thereby improving their accumulation and therapeutic efficacy at infection sites. This strategy provides a promising opportunity for overcoming the diffusion limitations encountered by conventional nanocarriers. Collectively, stomatocytes offer a versatile nanoplatform for antibacterial and anti-biofilm applications. Their high loading capacity, tunable structure, and surface engineering provide opportunities to integrate targeted drug delivery, stimuli-responsive release, catalytic biofilm disruption, and multimodal antimicrobial strategies within a single nanoplatform.

Although polymeric stomatocytes have been predominantly explored as drug delivery vehicles for cancer treatment and antimicrobial/anti-biofilm applications, their unique bowl-shaped morphology and compartmentalized structure may also offer opportunities in several emerging biomedical fields. One promising direction is the development of stomatocyte-based systems for cardiovascular therapy. The tunable polymeric membrane and accessible internal cavities allow the encapsulation of a broad range of therapeutic agents, including anti-inflammatory, antithrombotic, and vascular-protective molecules^[86,87]. Moreover, surface functionalization with ligands targeting activated endothelial cells, platelets, or atherosclerotic plaques could potentially enhance site-specific accumulation while minimizing off-target effects. The characteristic cavity and opening of stomatocytes provide opportunities for cargo loading and retention, as well as stimuli-responsive release, which may offer additional flexibility for localized therapeutic delivery. In addition, incorporation of catalytic enzymes or inorganic nanoparticles within the cavity could facilitate the in situ conversion of endogenous substrates into therapeutic products, which may be particularly relevant for cardiovascular disorders associated with oxidative stress and dysregulated metabolic microenvironments^[88]. Another intriguing application arises from the structural resemblance of stomatocytes to biological cells, particularly in the development of artificial red blood cell (RBC)-mimicking systems. A representative example was reported by Shao et al., who developed therapeutic nano-RBCs based on biodegradable PEG-PDLLA stomatocytes^[28]. In this design, hemoglobin was encapsulated within the stomatocyte cavity as an oxygen-carrying component, while the photosensitizer chlorin e6 was co-loaded to enable oxygen-enhanced photodynamic therapy. To further improve biomimicry and circulation behavior, erythrocyte-derived cell membranes were coated onto the stomatocyte surface, imparting selected biological characteristics of native RBCs. The resulting membrane-coated stomatocytes exhibited prolonged blood circulation and enhanced tumor accumulation in vivo, suggesting that biomimetic interfaces may complement the multifunctional and compartmentalized architecture of stomatocytes to improve their therapeutic potential. Ocular drug delivery represents another emerging application for stomatocytes. Recent studies have highlighted the potential of polymersomes as ocular nanocarriers, owing to their prolonged drug-release profiles, enhanced ocular retention, and tunable transport properties within ocular tissues^[89]. Compared with conventional spherical vesicles, stomatocytes feature a confined internal cavity connected to the external environment through a tunable opening. This architecture may facilitate the encapsulation and spatial organization of diverse therapeutic cargos, including small-molecule drugs, proteins, antioxidants, and neuroprotective agents. Furthermore, tuning the opening size could modulate cargo diffusion and release kinetics within the complex ocular microenvironment, potentially enabling sustained and localized drug delivery.

Collectively, these examples suggest that the distinctive morphology and compartmentalized structure of stomatocytes may broaden their applications beyond cancer therapy and antimicrobial applications. However, most of these emerging applications remain at an early stage of development, and further studies are needed to determine whether the structural advantages of stomatocytes translate into meaningful improvements in therapeutic efficacy, targeting, and clinical performance compared with conventional polymersomes and other established nanocarrier platforms.

Despite significant progress in the development of stomatocyte nanocarriers, their translation into clinical applications remains limited by manufacturing challenges^[90]. Most current preparation methods, including solvent-switch and osmotic-induced approaches, are optimized for laboratory-scale production and often involve multiple processing steps that are difficult to standardize. As production is scaled up, maintaining consistent particle characteristics, such as uniform hydrodynamic size, morphology, and the neck opening, becomes increasingly challenging. A major obstacle is achieving batch-to-batch consistency, as even slight variations in synthesis conditions, such as solvent composition, osmotic conditions, temperature, and processing time, can lead to differences in particle size, morphology, membrane thickness, and encapsulation efficiency. Such variability may in turn affect drug loading, therapeutic efficacy, and biodistribution. Therefore, the development of robust, scalable, reproducible, and economically feasible manufacturing processes that comply with Good Manufacturing Practice (GMP) standards is essential for future commercialization. Recent advances in manufacturing techniques, such as microfluidic-assisted self-assembly, flash nanoprecipitation, and automated in-line process monitoring, offer promising strategies to improve the large-scale and reliable production of stomatocytes^[91-93]. Addressing these challenges will be a critical step toward the clinical translation and commercialization of stomatocyte-based nanomedicines.

Maintaining the structural integrity of stomatocytes during storage and under physiological conditions is essential for preserving cargo retention and functional performance. However, compared with the extensive literature on stomatocyte formation and morphological transformation, systematic studies of their long-term stability remain limited. Available evidence suggests that environmental conditions can affect membrane organization, colloidal stability, and morphology, but the effects of temperature, osmotic stress, protein adsorption, and storage conditions have not been systematically evaluated across different stomatocyte formulations. Potential instability, including membrane rearrangement, aggregation, shape transformation, or premature cargo release, should therefore be considered as possible but system-dependent risks rather than universal characteristics. Temperature and osmotic conditions may be particularly important because changes in membrane fluidity, polymer-chain organization, and transmembrane osmotic pressure could alter stomatocyte morphology and cargo retention. Nevertheless, quantitative evidence linking these parameters to long-term stability remains scarce. Similarly, although lyophilization is widely used to improve nanocarriers’ storage stability, its applicability to stomatocytes requires system-specific validation, as dehydration and rehydration may affect morphology, aggregation, and cargo retention. Thus, low-temperature storage and lyophilization should not be assumed to be universally suitable preservation strategies. Following systemic administration, stomatocytes encounter a complex physiological environment involving ionic strength, osmolarity, plasma proteins, and hydrodynamic forces, which may affect surface interactions, colloidal stability, membrane properties, and cargo retention. Surface engineering strategies, including optimized PEGylation, zwitterionic modification, and biomimetic coatings, may reduce nonspecific protein adsorption and immune recognition, although their long-term immunological compatibility requires systematic evaluation, particularly for repeated administration. Future studies should therefore establish standardized stability assessment frameworks encompassing morphology, size distribution, membrane integrity, aggregation, and cargo retention under controlled variations in temperature, osmolarity, ionic strength, protein exposure, and storage duration. For lyophilized formulations, these parameters should be compared before and after freezing, drying, and rehydration. Importantly, structural stability should also be correlated with functional performance, including cargo release and, where applicable, catalytic or propulsion activity. Such systematic evaluation will help establish quantitative stability criteria, identify formulation-specific failure modes, and determine whether the distinctive stomatocyte architecture can be reliably maintained during storage and under physiologically relevant conditions.

Although stomatocytes prepared from different amphiphilic block copolymers have exhibited favorable biocompatibility, comprehensive evaluation of their long-term biosafety remains relatively limited^[94]. As stomatocyte-based nanocarriers advance toward clinical translation, establishing a comprehensive long-term safety profile will become increasingly important, particularly for chronic diseases, requiring repeated administration. Beyond conventional cytotoxicity assays, future investigations should systematically address chronic toxicity, immunogenicity, inflammatory responses, and the biological consequences of repeated dosing to better predict their long-term clinical performance. A major knowledge gap concerns the long-term in vivo fate of stomatocytes and their degradation products. Although many amphiphilic block copolymers are designed to be biodegradable under physiological conditions, their degradation kinetics, metabolic pathways, and clearance mechanisms remain incompletely characterized. In addition, prolonged retention or accumulation in organs associated with the mononuclear phagocyte system, such as the liver and spleen, may lead to chronic tissue burden or subtle functional impairment. Consequently, long-term studies integrating biodistribution, organ histopathology, biodegradation, and metabolic analyses are important for establishing a comprehensive understanding of chronic toxicity. Another important consideration is the potential interaction between stomatocytes and the immune system. Upon systemic administration, nanocarriers inevitably encounter plasma proteins and immune cells, which may trigger protein corona formation. Detailed profiling of pro-inflammatory cytokines and immune cell activation patterns is therefore essential to evaluate their immuno-inflammatory compatibility. Repeated exposure to nanocarriers may alter pharmacokinetics, biodistribution, and clearance behavior over time. Potential issues include accumulation in major organs, altered immune recognition after first exposure, and changes in therapeutic efficiency. Long-term repeated-dose studies are necessary to assess cumulative toxicity and to validate dosing regimens for safe translational application.

Despite substantial progress in demonstrating the motion of nanomotors in vitro and in vivo, their translation into physiologically relevant and clinically applicable systems remains challenging^[95]. General barriers include limited fuel availability, the complexity of physiological environments, immune recognition and clearance, and interference from blood flow. For stomatocyte-based nanomotors, however, these challenges may be further influenced by the distinctive interplay among polymer membrane integrity, stomatocyte morphology, confined cavity geometry, and propulsion behavior. In particular, the stability and degradation of the polymer membrane will determine propulsion performance over time. Changes in polymer composition, membrane thickness, surface properties, or overall stomatocyte integrity during degradation could alter the accessibility and spatial organization of catalytic components, as well as the transport of fuels and reaction products. These changes may, in turn, affect catalytic efficiency and propulsion behavior. Establishing quantitative correlations between polymer degradation, structural integrity, and propulsion characteristics will therefore be important for determining whether the propulsion performance observed under controlled experimental conditions can be maintained over relevant biological timescales. The confined cavity of stomatocytes represents a potentially important but comparatively underexplored feature that may distinguish these nanomotors from other motor architectures. Although the cavity and opening provide a defined spatial configuration for integrating catalytic components, confinement may either facilitate or hinder the diffusion and exchange of fuels and reaction products, depending on cavity dimensions, opening size, membrane permeability, and the surrounding medium. Consequently, the compartmentalized architecture that enables functional integration may also introduce mass-transfer limitations under certain physiological conditions. For example, confinement could potentially enhance local fuel conversion by increasing reactant residence time, but it could also reduce catalytic turnover by restricting molecular exchange. These context-dependent effects should therefore be considered when interpreting propulsion behavior and optimizing stomatocyte geometry for specific biological environments. Systematic studies correlating cavity architecture, catalytic activity, and propulsion kinetics under physiologically relevant conditions are needed to determine whether confinement represents a functional advantage, a limitation, or both depending on the operating environment.

Several strategies may help address these challenges. Fuel-independent propulsion driven by magnetic, acoustic, or light fields could reduce reliance on exogenous chemical fuels, while biologically available substrates such as glucose or urea may provide more physiologically compatible alternatives. Surface engineering with antifouling or biomimetic coatings may reduce protein adsorption and immune recognition, but their potential effects on membrane stability, cavity accessibility, and propulsion should also be carefully evaluated. External actuation and guidance may further help overcome hemodynamic forces and improve spatiotemporal control. Ultimately, the translation of stomatocyte-based nanomotors will require not only improved propulsion efficiency but also a clearer understanding of how polymer degradation, cavity confinement, and physiological interactions collectively influence propulsion stability and performance over relevant biological timescales.

The successful clinical translation of stomatocyte-based nanomedicine will rely not only on their therapeutic performance but also on their ability to satisfy increasingly strict regulatory and manufacturing requirements^[96]. As complex polymeric nanocarriers, stomatocytes must demonstrate consistent quality, safety, reproducibility, and scalability throughout their development. Consequently, establishing standardized manufacturing processes, validated quality control strategies, GMP compliant production, and well-defined regulatory pathways will be indispensable for their clinical and commercial implementation. A primary challenge lies in the standardization of manufacturing and characterization protocols. Reliable batch-to-batch reproducibility requires tight control over critical process parameters during stomatocyte fabrication, together with standardized analytical methods to evaluate physicochemical properties, drug loading efficiency, encapsulation stability, and release behavior. Sterility represents another important element. Conventional sterilization methods may compromise the structural integrity and biological functionality of stomatocytes, particularly for formulation encapsulating enzymes or other fragile therapeutics. Aseptic manufacturing using sterile raw materials is likely to represent the most practical strategy for clinical production. Importantly, sterilization procedures should be validated to ensure that particle morphology, cargo loading, catalytic activity, and therapeutic performance remain unaffected. Beyond laboratory-scale fabrication, the transition to GMP manufacturing requires production processes that are scalable, reproducible, and readily validated. Traditional batch-based preparation methods frequently suffer from limited scalability and process variability, presenting significant barriers to industrial translation. Continuous manufacturing approaches, such as microfluidic assembly and automated solvent exchange systems, offer enhanced process control, improved reproducibility, and greater manufacturing consistency, making them promising candidates for large-scale GMP production of stomatocyte formulations. Regulatory approval of stomatocyte-based nanomedicines should follow existing frameworks established for liposomes formation, polymeric nanoparticles, or other nanomedicines.

The rapid advancement of artificial intelligence (AI) and machine learning (ML) is reshaping the development of nanomedicine by enabling data-driven optimization of formulation design, predictive modeling of nanocarrier performance, reduction of experimental workload, and accelerated clinical translation^[97,98]. Recent advances in machine learning have demonstrated the potential to accelerate the design and optimization of polymeric nanocarriers by linking formulation parameters with physicochemical and biological outcomes. For example, machine-learning models have been applied to predict nanoparticle size, drug-loading efficiency, and cellular uptake based on polymer composition and formulation parameters, thereby enabling data-driven optimization of polymeric delivery systems^[99-102]. Similar approaches could be extended to stomatocytes by integrating descriptors such as block-copolymer composition, molecular weight, hydrophilic-to-hydrophobic balance, opening size, cavity dimensions, cargo characteristics, preparation conditions, and surface functionalization. Such models may ultimately facilitate the prediction and optimization of cargo encapsulation and retention, stimulus-responsive release, colloidal stability, and biodistribution. However, AI-guided design of stomatocytes remains at an early stage and will require sufficiently large, standardized, and experimentally validated datasets to achieve reliable predictive performance.

Beyond formulation optimization, AI is expected to transform the characterization and manufacturing of stomatocyte nanocarriers. Advanced image analysis algorithms can automatically quantify morphological features, identify structural defects, and classify heterogeneous stomatocyte populations with greater accuracy and reproducibility than manual analysis^[103]. When integrated with automated synthesis platforms and high-throughput experimentation, these approaches may establish closed-loop optimization systems capable of continuously refining fabrication parameters and improving production consistency. AI also provides an unprecedented opportunity to establish quantitative structure-function relationships for stomatocyte-based nanocarriers. By integrating experimental characterization, molecular simulations and datasets, ML models can identify the structural determinants that govern pharmacokinetics, biodistribution, tumor accumulation, intracellular delivery, and therapeutic efficacy. Most importantly, combining AI with molecular dynamics simulations, finite-element analysis, and computational fluid dynamics could enable multiscale prediction of stomatocyte behavior across molecular, cellular and physiological levels, providing mechanistic insights that are difficult to obtain experimentally.

Looking forward, the integration of AI may support the development of personalized stomatocyte therapeutics. Predictive models incorporating nanocarrier characteristics together with patient-specific clinical information could facilitate the rational design of individualized formulations with optimized targeting efficiency, drug loading, and dosing strategies. As these techniques continue to mature, AI-guided design is expected to be a driving force for the next generation of stomatocytes in nanomedicine, accelerating their translation from laboratory research to clinical applications.

The next generation of stomatocyte-based nanocarriers may increasingly incorporate biomimetic and biohybrid design strategies to address biological barriers that continue to limit the clinical translation of conventional nanocarriers^[104,105]. By integrating naturally derived biological components with engineered stomatocytes, these hybrid systems could combine the structural programmability of synthetic polymeric nanocarriers with selected biological functions of living cells. Such integration may help modulate immune recognition, prolong systemic circulation, and improve tissue-specific interactions, potentially expanding the therapeutic applications of stomatocytes. One promising strategy is the functionalization of stomatocytes with cell membranes^[106,107]. These biomimetic interfaces provide membrane proteins, lipids, and glycocalyx components that can influence immune recognition and cell-nanocarrier interactions, thereby offering opportunities to improve circulation behavior and facilitate targeted delivery. Beyond cell membrane coating, exosome-inspired engineering represents another promising direction for stomatocyte design. As naturally occurring extracellular vesicles involved in intercellular communication, exosomes exhibit favorable biocompatibility and cellular uptake properties and can carry diverse biomolecular cargos. Future stomatocyte platforms could incorporate selected structural and functional features of exosomes while retaining the architectural and engineering advantages of stomatocytes. Incorporation of exosomal membrane proteins, extracellular vesicle-derived lipids, or bioactive targeting ligands may facilitate interactions with specific cell types and potentially improve transport across biological barriers. Such hybrid systems may be particularly relevant for the delivery of nucleic acids, gene-editing components, therapeutic proteins, and immunomodulatory agents, for which efficient cellular uptake and controlled immune interactions are important. However, whether exosome-inspired modifications can provide consistent advantages over conventional stomatocytes remains to be systematically established.

Translating active nanomotors into clinical applications remains limited because most propulsion strategies rely on exogenous chemical fuels that are either absent from or incompatible with physiological environments. Rather than continuing to maximize propulsion speed or efficiency, the next generation of stomatocyte-based nanomotors should prioritize clinically translatable actuation strategies that are biocompatible, externally controllable, and readily integrated with existing medical technologies^[108,109]. From this review, fuel-free propulsion, magnetic actuation, ultrasound-driven locomotion, and intelligent in vivo motion regulation represent particularly promising directions. A major challenge is the replacement of chemically fueled propulsion systems, which commonly depend on hydrogen peroxide or other nonphysiological reactants with limited biocompatibility and potential toxicity. Future designs should instead exploit endogenous energy sources available within biological systems. Examples include propulsion driven by naturally occurring biochemical gradients, enzyme-mediated metabolic reactions, or biohybrid systems powered by living cells or microorganisms. Such approaches not only eliminate the need for exogenous fuels but also improve compatibility with complex physiological environments.

Among externally powered strategies, magnetic actuation is particularly attractive for clinical translation. Magnetic fields penetrate deep tissues noninvasively and are already widely used in clinical imaging and interventional medicine. Incorporating magnetic nanoparticles into stomatocytes enables remote guidance, directional navigation, and enhanced retention at disease sites while simultaneously allowing integration with magnetic resonance imaging (MRI) for real-time tracking and image-guided therapy. Ultrasound provides another highly promising actuation modality owing to its deep tissue penetration and widespread clinical availability. Acoustic propulsion, generated through mechanisms such as acoustic streaming, radiation forces, or microbubble oscillation, enables efficient locomotion without chemical fuels and is therefore well suited for applications in deep or otherwise inaccessible tissues. Looking forward, the development of active stomatocytes should extend beyond the pursuit of increasingly sophisticated propulsion mechanisms toward the creation of intelligent nanomotors capable of adaptive and programmable motion. By integrating responsiveness to external physical cues (e.g., magnetic fields or ultrasound) with endogenous biological signals associated with disease microenvironments, stomatocyte nanomotors could achieve on-demand activation, autonomous behavioral adaptation, and spatiotemporally precise navigation.

The merger of nanotechnology and precision medicine is driving a shift from conventional “one-size-fits-all” therapeutics toward highly individualized treatment tailored to patient-specific biological characteristics^[110]. In this context, stomatocyte-based nanocarriers offer a versatile platform that can be engineered with multifunctionality and stimuli-responsiveness to meet the demands of precision and personalized medicine. These systems can be readily functionalized with targeting ligands, antibodies, peptides, or aptamers to recognize disease-associated biomarkers expressed in a patient-specific manner on diseased tissues or cells. Beyond molecular targeting, personalization can also be achieved by leveraging interpatient variability in tumor microenvironment features, thereby enhancing therapeutic selectivity, reducing off-target toxicity, and addressing the biological heterogeneity that often limits the efficacy of conventional treatments^[111]. The integration of companion diagnostics is therefore essential to identify patient subpopulations most likely to benefit from stomatocyte-based therapies. By incorporating imaging agents or molecular probes into stomatocytes, it becomes possible to classify patients based on biomarker expression profiles, biodistribution behavior, or microenvironmental features^[112]. Such theranostic capabilities further enable real-time feedback to optimize dosing schedule and delivery method in a patient-specific manner. Overall, the integration of targeted delivery, companion diagnostics, and theranostic functionality positions stomatocyte-based systems as a promising platform for advancing precision and personalized nanomedicine.